SG11201701135WA - Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition - Google Patents

Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Info

Publication number
SG11201701135WA
SG11201701135WA SG11201701135WA SG11201701135WA SG11201701135WA SG 11201701135W A SG11201701135W A SG 11201701135WA SG 11201701135W A SG11201701135W A SG 11201701135WA SG 11201701135W A SG11201701135W A SG 11201701135WA SG 11201701135W A SG11201701135W A SG 11201701135WA
Authority
SG
Singapore
Prior art keywords
compositions
preventing
conditions
methods
extracellular matrix
Prior art date
Application number
SG11201701135WA
Inventor
Cynthia Lander
Colleen Brophy
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of SG11201701135WA publication Critical patent/SG11201701135WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
SG11201701135WA 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition SG11201701135WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/473,339 US9890200B2 (en) 2011-04-12 2014-08-29 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PCT/US2015/047390 WO2016033432A1 (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (1)

Publication Number Publication Date
SG11201701135WA true SG11201701135WA (en) 2017-03-30

Family

ID=52583553

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701135WA SG11201701135WA (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Country Status (12)

Country Link
US (2) US9890200B2 (en)
EP (1) EP3185883A4 (en)
JP (1) JP2017528454A (en)
KR (1) KR20170044171A (en)
CN (1) CN107073075A (en)
AU (1) AU2015308761A1 (en)
BR (1) BR112017003731A2 (en)
CA (1) CA2958085A1 (en)
MX (1) MX2017002476A (en)
RU (1) RU2017110093A (en)
SG (1) SG11201701135WA (en)
WO (1) WO2016033432A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
SG11201705559RA (en) 2015-01-08 2017-08-30 Moerae Matrix Inc Formulation of mk2 inhibitor peptides
JP2018512401A (en) * 2015-03-12 2018-05-17 モイライ マトリックス インコーポレイテッド Use of MK2 inhibitor peptide-containing composition for the treatment of non-small cell lung cancer
CN112920256B (en) * 2019-11-21 2022-08-19 上海医药工业研究院 Biological peptide for treating asthma and application thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GR79615B (en) 1982-10-08 1984-10-31 Glaxo Group Ltd
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (en) 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
CA2118513A1 (en) 1992-04-24 1993-11-11 David A. Zarling In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CN1048254C (en) 1993-12-09 2000-01-12 托马斯杰弗逊大学 Compounds and methods for site-directed mutations in eukaryotic cells
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6440463B1 (en) 1999-04-05 2002-08-27 Pharmaceutical Discovery Corporation Methods for fine powder formation
DK2280020T3 (en) 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
WO2003090682A2 (en) 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP2298810A3 (en) 2002-07-19 2011-08-03 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (en) 2004-08-23 2023-01-10 Mannkind Corporation THERAPEUTIC DRY POWDER COMPOSITION CONTAINING DICETOPIPERAZINE, AT LEAST ONE TYPE OF CATION AND ONE BIOLOGICALLY ACTIVE AGENT
WO2006023944A2 (en) 2004-08-23 2006-03-02 Mannkind Corporation Pulmonary delivery of inhibitors of phosphodiesterase type 5
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
KR20080105174A (en) * 2006-04-03 2008-12-03 테바 파마슈티컬 인더스트리즈 리미티드 Drug microparticles
CA2689296C (en) 2007-01-10 2015-11-17 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
US8063094B2 (en) 2007-02-08 2011-11-22 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
JP5785085B2 (en) 2008-10-20 2015-09-24 モイライ マトリックス インコーポレイテッド Polypeptide for treating or preventing adhesions
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
EP2575855A4 (en) 2010-05-24 2014-03-12 Moerae Matrix Inc Methods for treating or preventing vascular graft failure
KR101862291B1 (en) 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Also Published As

Publication number Publication date
RU2017110093A3 (en) 2018-10-01
US10562947B2 (en) 2020-02-18
US20180194817A1 (en) 2018-07-12
MX2017002476A (en) 2017-08-14
EP3185883A1 (en) 2017-07-05
RU2017110093A (en) 2018-10-01
EP3185883A4 (en) 2018-05-30
WO2016033432A9 (en) 2016-04-21
US20150064134A1 (en) 2015-03-05
AU2015308761A1 (en) 2017-02-23
CN107073075A (en) 2017-08-18
CA2958085A1 (en) 2016-03-03
KR20170044171A (en) 2017-04-24
US9890200B2 (en) 2018-02-13
JP2017528454A (en) 2017-09-28
WO2016033432A1 (en) 2016-03-03
BR112017003731A2 (en) 2017-12-05

Similar Documents

Publication Publication Date Title
HK1255005A1 (en) Compositions and methods for preventing or treating diseases characterized by aberrant fibroblast proliferation and extracellular matrix deposition
ZA201703305B (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
SG11201705093UA (en) Composition for treating il-6-related diseases
PT3261640T (en) 5ht agonists for treating disorders
PL3167096T3 (en) Two-step deposition process
EP3501527C0 (en) Composition for preventing or treating mental disorder, containinglactobacillus
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
IL250715A0 (en) Compositions and methods for treating proliferation disorders
IL259486A (en) Agents for the treatment of diseases associated with undesired cell proliferation
ZA201705148B (en) Pharmaceutical composition for treating cancer, containing lactate metal salt
EP3269084A4 (en) Subscriber identity pattern
HK1244211A1 (en) Method for treating, preventing, or reducing the risk of skin infection
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
HK1213937A1 (en) Durable antimicrobial coating composition
SG11201701135WA (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP3326638A4 (en) Pharmaceutical composition for preventing or treating il-6-mediated diseases comprisingrosa rugosa
GB201515985D0 (en) Deposition process
HK1232128A1 (en) Pharmaceutical composition for preventing or treating skin rash
SG11201704701YA (en) Pharmacotherapy for preventing or treating glaucoma
KR101894521B9 (en) Topical pharmaceutical composition for treating scar
PT3565592T (en) Methods for treating metabolic diseases by inhibiting myostatin activation
EP3305293A4 (en) Method for treating or preventing diabetic nephropathy
EP3210602A4 (en) Composition for preventing or treating neurodegenerative diseases, containing ramalin
EP3354271A4 (en) Agent for treating arthrological diseases